Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

321.50 -4.53 (-1.39%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Is Medpace Stock Diving On Tuesday?
Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast. 
Via Benzinga
How Medpace Just Blew Up Expectations For Double-Digit Sales Growth In 2025
The contract research organization missed bookings expectations, but didn't offer into any insight into the impact for 2025. 
Via Investor's Business Daily
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Sherwin-Williams Posts Weak Results, Joins Logitech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Insights Ahead: Medpace Hldgs's Quarterly Earnings
Via Benzinga
Exploring Medpace Hldgs's Earnings Expectations
Via Benzinga
Earnings Preview For Medpace Hldgs
Via Benzinga
Examining the Future: Medpace Hldgs's Earnings Outlook
Via Benzinga
A Look at Medpace Hldgs's Upcoming Earnings Report
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Medpace Holdings, Inc. Reports Third Quarter 2024 Results
From Medpace Holdings, Inc.
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Medpace Hldgs
Via Benzinga
Looking Into Medpace Hldgs's Recent Short Interest
Via Benzinga
Assessing Medpace Hldgs: Insights From 9 Financial Analysts
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Centuri, Medpace, and Franklin and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Cardlytics, Medpace, Customers Bancorp, and Ibotta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Medpace Hldgs
Via Benzinga
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
Medpace Holdings, Inc. to Report Third Quarter 2024 Financial Results on October 21, 2024
From Medpace Holdings, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 Years
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Via Benzinga
How to Analyze a Balance Sheet
Real-life examples to help investors make sense of this critical document. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Medpace and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.